Vera Therapeutics, Inc.

NasdaqGM:VERA Stock Report

Market Cap: US$2.4b

Vera Therapeutics Valuation

Is VERA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of VERA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VERA?

Key metric:

The above table shows the Price to Book ratio for VERA. This is calculated by dividing VERA's market cap by their current book value.
What is VERA's PB Ratio?
PB Ratio8.2x
BookUS$289.06m
Market CapUS$2.37b

Price to Book Ratio vs Peers

How does VERA's PB Ratio compare to its peers?

The above table shows the PB ratio for VERA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.9x
CNTA Centessa Pharmaceuticals
4.5x13.0%US$2.2b
SLNO Soleno Therapeutics
8.2x58.4%US$2.1b
BEAM Beam Therapeutics
2.6x-2.1%US$2.2b
PTGX Protagonist Therapeutics
4.2x0.9%US$2.3b
VERA Vera Therapeutics
8.2x36.4%US$2.4b

Price to Book Ratio vs Industry

How does VERA's PB Ratio compare vs other companies in the US Biotechs Industry?

70 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.4x26.9%US$1.06b
SLRN Acelyrin
0.4x16.8%US$198.64m
LYEL Lyell Immunopharma
0.3x-13.7%US$170.39m
NKTX Nkarta
0.4x-8.3%US$166.54m
VERA 8.2xIndustry Avg. 1.8xNo. of Companies79PB01.63.24.86.48+
70 CompaniesEstimated GrowthMarket Cap
No more companies

Price to Book Ratio vs Fair Ratio

What is VERA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VERA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.2x
Fair PB Ration/a

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 14:55
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vera Therapeutics, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Liisa BaykoEvercore ISI
Paul ChoiGoldman Sachs